<DOC>
	<DOCNO>NCT00985946</DOCNO>
	<brief_summary>This summary use Panobinostat ( LBH589 ) patient neuroendocrine tumor see patient 's tumor respond panobinostat . Additionally , study examine long take neuroendocrine tumor patient 's cancer progress take drug examine overall survival patient use panobinostat . Also , study examine toxicity tolerability panobinostat patient population . Finally , study look effect panobinostat Notch 1 signal treatment panobinostat .</brief_summary>
	<brief_title>Study Panobinostat Patients With Neuroendocrine Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<criteria>Histologically confirm , metastatic , low grade neuroendocrine neoplasm . Small cell lung cancer , paragangliomas , pheochromocytoma exclude Must measurable disease define RECIST 4 week completion major surgery , chemotherapy , systemic therapy local liver therapy study registration . Concurrent octreotide allow . Not allow concurrent chemotherapy radiation 18 year age old ECOG Performance status equal le 2 Able sign date write informed consent prior participation study Baseline MUGA ECHO must demonstrate LVEF great equal low limit institutional normal Must follow laboratory criterion : Neutrophil count great 1500/mm3 , platelet count great 100,000/mm3L , hemoglobin great equal 9 g/dL , AST/SGOT ALT/SGPT less equal 2.5 x ULN , serum bilirubin less equal 1.5 x ULN , serum creatinine less equal 1.5 x ULN , total serum calcium great equal LLN , serum potassium great equal LLN , serum sodium great equal LLN , serum albumin great equal LLN 3g/dl , Women child bear potential must negative urine pregnancy test within 72 hour first administration study treatment must willing use two method contraception Patients history hypertension must well control ( less 150/90 mmHg ) stable regimen antihypertensive therapy Prior HDAC , DAC , HSP90 inhibitor valproic acid treatment cancer Patients need valproic acid medical condition study within 5 day prior first panobinostat treatment Impaired cardiac function include follow : Screening ECG QTc great 450 msec , patient congenital long QT syndrome , history unsustained ventricular tachycardia , history ventricular fibrillation torsades de pointes , bradycardia define heart rate le 50 beat per minute , patient myocardial infarction unstable angina within 6 month study entry , congestive heart failure , right bundle branch block leave anterior hemiblock Uncontrolled hypertension Unresolved diarrhea great CTCAE grade 1 Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption oral panobinostat Other concurrent sever and/or uncontrolled medical condition Patients history another primary malignancy , opinion investigator , would interfere assessment primary endpoint study Patients know positivity human immunodeficiency virus ( HIV ) hepatitis C , baseline testing require Any significant history noncompliance medical regimen inability grant reliable informed consent Any medication may cause QTc prolongation induce torsades de pointes Use concomitant medication may interact panobinostat</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>